New Delhi: Government of India has announced a third incentive package of Rs 900 crore for Mission Covid Security – Indian Covid-19 Vaccine Development Mission. The grant will be provided to the Department of Biotechnology (DBT) for research and development of the Indian Covid-19 vaccine.
Covid-19 Vaccine Development Mission; The pre-clinics will consolidate all available and funded resources for accelerated product development, with a focus on development, manufacturing and deployment with a regulatory facility. This will help in the development of 5-6 vaccine candidates and ensure licensing and market access. These vaccine candidates will be considered by regulatory authorities upon its introduction into the public health system to combat the spread of covid infection.
Funds will have important objectives to support Covid-19 vaccine development – accelerating pre-clinical and clinical development; Licensing for Covid-19 Vaccine Candidates, who are currently in the clinical stages or ready to enter the clinical phase of development, establishing clinical trial sites and existing resistance testing laboratories, Central To strengthen laboratories, facilities suitable for studies on animals, production facilities and other testing facilities. Other important objectives will be to support the development of common harmonized protocols, training, data management systems, regulatory presentations, internal and external quality management systems and accreditation. The mission will also support the capabilities of manufacturing GMP batches for process development, cell line development and animal toxicology studies and clinical trials. Developing a suitable target product profile will also be a major task so that the vaccines offered through the mission are in line with India requirements.
The mission, led by the Department of Biotechnology and implemented by the dedicated Mission Implementation Unit of the Biotechnology Industry Research Assistance Council (BIRAC), will provide complementary strengths to the existing activities of the National Bio-Pharma Mission (NBM) and the Ind-CEPI Mission.
Phase-I of the Covid Security Mission has been allocated Rs 900 crore for a period of 12 months.
So far, a total of 10 vaccine candidates have been supported by the Department of Biotechnology, both in the academic world and in the industry. Currently, 5 vaccine candidates, including the Russian vaccine Sputnik-V, are under human trials, while 3 others are in the pre-clinical advance stage, which will soon begin human trials.
Dr. Renuswarup, Secretary, Department of Biotechnology, Ministry of Science and Technology, and Chairperson of BIRAC, said, “Mission Covid Security is our targeted effort to develop indigenous, affordable and accessible vaccines for our country and this is part of the self-reliant India National Mission Will prove to be complementary. ” He said, India is a powerful nation in vaccine manufacturing and through this National Covid Vaccine Mission, we are confident that our vaccine manufacturers will develop affordable and accessible vaccines for not only India but the world.